TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20165986

Group type: EXPERIMENTAL
Intervention: Combination therapy comprising intravenous application of platinum and paclitaxel
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Macroscopically complete resection
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Residual disease of 0.1-1 cm and residual tumor of >1 cm
Number of subjects: 573
Study: 17684064

Group type: EXPERIMENTAL
Intervention: Bifocal pacing
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control pacing
Number of subjects: 42
Study: 16273808

Group type: EXPERIMENTAL
Intervention: Finnish RA Combination Therapy Trial (FIN-RACo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central Finland RA Database
Number of subjects: 0
Study: 12421195

Group type: EXPERIMENTAL
Intervention: Dopexamine (1 micro g. kg‐1. min‐1) continuously after induction of anesthesia until 18 h after CPB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural infusion of bupivacaine 0.25% [(body height (cm) - 100). 10-1=ml.h-1] for the whole study period
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (NaCl 0.9%) in a time-matched fashion
Number of subjects: 40
Study: 9866364

Group type: EXPERIMENTAL
Intervention: New bed utilization program
Number of subjects: 103

Group type: COMPARATOR
Intervention: Pre-implementation (control)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Post-implementation (intervention)
Number of subjects: 103
Study: 8554435

Group type: EXPERIMENTAL
Intervention: Timed intrauterine insemination (IUI) without hyperstimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sexual intercourse
Number of subjects: 0
Study: 2687355

Group type: EXPERIMENTAL
Intervention: Pyritinol
Number of subjects: 26
Study: 31606605

Group type: EXPERIMENTAL
Intervention: New fissure-attached nodules
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: New fissure-attached malignant nodules
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Overall nodules detected
Number of subjects: 949
Study: 28078617

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 105
Study: 28429117

Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Number of subjects: 75

Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 75
Study: 25761503

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 743

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 743
Study: 23281694

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 14

Group type: COMPARATOR
Intervention: 308-nm excimer lamp
Number of subjects: 14
Study: 21415357

Group type: EXPERIMENTAL
Intervention: HPV positive women diagnosed with CIN3+ (n = 448)
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: HPV positive women with normal Pap
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: HPV positive women with abnormal Pap
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Age-related trends
Number of subjects: 1278
Study: 18211117

Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg and dimenhydrinate 40 mg three times daily for 4 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Betahistine 12 mg three times daily for 4 weeks
Number of subjects: 66
Study: 16608150

Group type: EXPERIMENTAL
Intervention: Real beer (mean breath alcohol concentration of .115 g%)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo beer
Number of subjects: 61
Study: 12915338

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 to 3000 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10789176

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with sponge anesthesia and intraocular injection of 0.15 ml lidocaine 1%
Number of subjects: 186

Group type: COMPARATOR
Intervention: Peribulbar injection of 6 ml Xylonest 2%
Number of subjects: 186
Study: 8795476

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine patch (Transderm, 0.05 mg/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo skin patch
Number of subjects: 12
Study: 1295415

Group type: EXPERIMENTAL
Intervention: 50g OGTT
Number of subjects: 56

Group type: COMPARATOR
Intervention: 75g OGTT
Number of subjects: 56
Study: 6432839

Group type: EXPERIMENTAL
Intervention: Single modified Thayer-Martin triplate
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Two swabs from each site (one for standard plate, one for triplate)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Triplate method
Number of subjects: 172
Study: 30905926

Group type: EXPERIMENTAL
Intervention: Metformin combined group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Insulin group
Number of subjects: 80
Study: 29131799

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 147
Study: 26952590

Group type: EXPERIMENTAL
Intervention: 20-mg oral d-amphetamine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 23396551

Group type: EXPERIMENTAL
Intervention: Aliskiren (6 months)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Traditional anti-hypertensive therapy (Control)
Number of subjects: 78
Study: 22125196

Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy Crohn's Disease Activity Index (CECDAI)
Number of subjects: 62
Study: 20061429

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 18059581

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle warm-up (IMW) consisting of two sets of 30-breath manoeuvres with an inspiratory pressure-threshold load equivalent to 40% maximum inspiratory mouth pressure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA) trial with inspiratory pressure-threshold load equivalent to 15% maximum inspiratory mouth pressure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control trial (no IM warm-up)
Number of subjects: 10
Study: 15855584

Group type: EXPERIMENTAL
Intervention: NeuroQuick (NQT)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Medoc warm TPT
Number of subjects: 348

Group type: COMPARATOR
Intervention: Medoc cold TPT
Number of subjects: 348

Group type: COMPARATOR
Intervention: TipTherm
Number of subjects: 348

Group type: COMPARATOR
Intervention: Tuning fork
Number of subjects: 348
Study: 11994349

Group type: EXPERIMENTAL
Intervention: 2 mg DNG
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5 mg DNG
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10 mg DNG
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10 mg cyproterone acetate
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 9705044

Group type: EXPERIMENTAL
Intervention: Amlodipine (up to 10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lisinopril (up to 20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both Amlodipine and Lisinopril
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 60
Study: 7602436

Group type: EXPERIMENTAL
Intervention: Concern about legal problems
Number of subjects: 438

Group type: COMPARATOR
Intervention: No legal factors
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Legal circumstances
Number of subjects: 438
Study: 2142292

Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: fenoterol after a prior single administration of prednisone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: adrenaline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: isotonic saline solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: vasoconstriction
Number of subjects: 100
Study: 688256

Group type: EXPERIMENTAL
Intervention: cis‐dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m2/day by iv push on Days 1‐5 every 4 weeks, followed by cyclophosphamide (C) at a dose of 400 mg/m2 and adriamycin (A) at a dose of 40 mg/m2 upon progression or renal toxic effects.
Number of subjects: 41

Group type: COMPARATOR
Intervention: C‐A (cyclophosphamide and adriamycin) at a dose of 400 mg/m2 and 40 mg/m2 respectively, given by iv push on Day 1 every 4 weeks.
Number of subjects: 41

Group type: COMPARATOR
Intervention: CAP‐I (C‐A plus concurrent P at 40 mg/m2 by IV push on Day 1 every 4 weeks).
Number of subjects: 41
Study: 31324214

Group type: EXPERIMENTAL
Intervention: Electric heating moxibustion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 40
Study: 28923098

Group type: EXPERIMENTAL
Intervention: Baricitinib monotherapy (4 mg once daily)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Baricitinib + MTX (4 mg once daily + MTX administered once weekly)
Number of subjects: 584
Study: 23456731

Group type: EXPERIMENTAL
Intervention: Yun-cai tea
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23129823

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 11
Study: 20674888

Group type: EXPERIMENTAL
Intervention: Decoupling (DC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 42
Study: 18452445

Group type: EXPERIMENTAL
Intervention: Community-treated patients with lifetime history of rapid cycling (RC)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Tertiary care treated patients with lifetime history of rapid cycling (RC)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Community-treated patients with lifetime history of RC
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Tertiary care treated patients with lifetime history of RC
Number of subjects: 359

Group type: COMPARATOR
Intervention: Tertiary care treated subjects with lifetime history of RC
Number of subjects: 359
Study: 15848574

Group type: EXPERIMENTAL
Intervention: EC‐MPS 720 mg b.i.d. (equimolar to MMF 1000 mg b.i.d.)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: EC‐MPS 450 or 432 mg/m2 b.i.d. for children
Number of subjects: 237

Group type: COMPARATOR
Intervention: MMF (< or =1000 mg b.i.d.)
Number of subjects: 237
Study: 11888226

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 5 microg/kg followed by 0.3 microg/kg per hour infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 3 microg/kg followed by 0.3 microg/kg per hour infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 microg/kg followed by 0.3 microg/kg per hour infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: NaCl 0.9% bolus and continuous infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (all doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 80
Study: 9498511

Group type: EXPERIMENTAL
Intervention: Splanchnic/antioxidant therapy (folate, mannitol, low-dose isoproterenol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Splanchnic/antioxidant therapy group
Number of subjects: 20
Study: 18475395

Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 2194935

Group type: EXPERIMENTAL
Intervention: Combined laboratory-clinical research settings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional laboratory research settings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical research settings
Number of subjects: 0
Study: 353464

Group type: EXPERIMENTAL
Intervention: Silymarin (2 sugar-coated tablets 70 mg three times daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31030266

Group type: EXPERIMENTAL
Intervention: 1-day regimen of antimicrobial prophylaxis
Number of subjects: 480

Group type: COMPARATOR
Intervention: 3-day regimen of antimicrobial prophylaxis
Number of subjects: 480
Study: 27231236

Group type: EXPERIMENTAL
Intervention: High Five for Kids intervention (intensive 1-year intervention followed by a 1-year maintenance period)
Number of subjects: 441
Study: 26297371

Group type: EXPERIMENTAL
Intervention: Active tDCS plus exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS plus exercise
Number of subjects: 20
Study: 23873171

Group type: EXPERIMENTAL
Intervention: HPV16/18 vaccine
Number of subjects: 7466

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 7466
Study: 21932579

Group type: EXPERIMENTAL
Intervention: Optimized Mixed Diet (OMD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-Glycemic Index Diet (low-GI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Both OMD and low-GI
Number of subjects: 17
Study: 18986845

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermal contact (heater probe, bipolar electrocoagulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sclerosant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clips
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bolus followed by continuous-infusion proton pump inhibitor
Number of subjects: 0
Study: 17976093

Group type: EXPERIMENTAL
Intervention: Multielectrode basket catheter (MBC) for pulmonary vein isolation (PVI)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Focal ablation guided by MBC
Number of subjects: 200
Study: 15562880

Group type: EXPERIMENTAL
Intervention: Sublingual swallow immunotherapy with ragweed allergen extract
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 11566454

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone treatment (6 mg/day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 9623371

Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hand-held Doppler
Number of subjects: 32
Study: 7821475

Group type: EXPERIMENTAL
Intervention: Amethocaine cream
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Amethocaine vs EMLA
Number of subjects: 169
Study: 3076791

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (continuous infusion and 6‐hourly divided dose regimens)
Number of subjects: 22
Study: 29071556

Group type: EXPERIMENTAL
Intervention: Probucol combined with hydration (probucol 500 mg twice daily and hydration)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Hydration only (control group)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Probucol combined with hydration
Number of subjects: 641

Group type: COMPARATOR
Intervention: Probucol combined with hydration and hydration only
Number of subjects: 641
Study: 27784336

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26084979

Group type: EXPERIMENTAL
Intervention: Structured mobile phone‐based health coaching program supported by a remote monitoring system
Number of subjects: 517

Group type: COMPARATOR
Intervention: Current practice (control)
Number of subjects: 517
Study: 22686135

Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention (diet and exercise)
Number of subjects: 61
Study: 19780631

Group type: EXPERIMENTAL
Intervention: SCTG with Er:YAG laser application
Number of subjects: 12

Group type: COMPARATOR
Intervention: SCTG without Er:YAG laser application (control group)
Number of subjects: 12
Study: 18685499

Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis DSM 18350, B. adolescentis DSM 18352, Bifidobacterium pseudocatenulatum DSM 18353 (5 x 10^9 colony forming units/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis DSM 18352
Number of subjects: 23
Study: 14767696

Group type: EXPERIMENTAL
Intervention: BDX + GTR
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BDX Coll + GTR
Number of subjects: 8
Study: 11594260

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9572083

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (amino acid beverage containing no tryptophan)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham depletion (amino acid beverage containing tryptophan)
Number of subjects: 11
Study: 7786690

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 95

Group type: COMPARATOR
Intervention: Intravenous propranolol
Number of subjects: 95
Study: 3208796

Group type: EXPERIMENTAL
Intervention: Porcine calcitonin in physiological saline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Porcine calcitonin in hydrolysed gelatin
Number of subjects: 9
Study: 28796014

Group type: COMPARATOR
Intervention: Primary Wound Closure (PC)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Delayed Primary Wound Closure (DPC)
Number of subjects: 604
Study: 27762569

Group type: EXPERIMENTAL
Intervention: Motivational check-in (MCI); 3 MET-based check-in sessions at 4, 7, and 10 months after baseline.
Number of subjects: 252

Group type: COMPARATOR
Intervention: Assessment-only check-in (ACI); 3 assessment-only check-in sessions at 4, 7, and 10 months after baseline.
Number of subjects: 252
Study: 24811580

Group type: EXPERIMENTAL
Intervention: ALP Animated Graphics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Picture Communication Symbols (PCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Animated symbols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALP symbols for prepositions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 0
Study: 21981307

Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment (IBA)
Number of subjects: 169
Study: 21055705

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 21

Group type: COMPARATOR
Intervention: Without taping
Number of subjects: 21
Study: 17609022

Group type: EXPERIMENTAL
Intervention: Podophyllin 25% and cryotherapy concurrently
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Trichloracetic acid or podophyllin 25% (single therapy)
Number of subjects: 409
Study: 15625221

Group type: EXPERIMENTAL
Intervention: Educational video about the consent process in treatment research
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control videotape presenting general information about bioethical issues in human research
Number of subjects: 0
Study: 11682424

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% plus epinephrine 1:200,000
Number of subjects: 41

Group type: COMPARATOR
Intervention: Plain ropivacaine 0.5%
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus epinephrine 1:200,000
Number of subjects: 41

Group type: COMPARATOR
Intervention: Plain ropivacaine 0.2%
Number of subjects: 41
Study: 9462166

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (Vitamin E) 600 mg twice a day for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7949636

Group type: COMPARATOR
Intervention: Single oral dose of cisapride (5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral cisapride (15 mg TID) for 14 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single oral dose of cisapride (5 mg) after 14 days of treatment
Number of subjects: 8
Study: 2897556

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: No hypnotherapy (Control)
Number of subjects: 30
Study: 31690049

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/bm)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 13
Study: 28121915

Group type: EXPERIMENTAL
Intervention: Moderate exercise in hypoxia (4200 m)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Moderate exercise in normoxia
Number of subjects: 9
Study: 25727442

Group type: EXPERIMENTAL
Intervention: Varenicline tablets
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nicotine patches
Number of subjects: 140
Study: 23843980

Group type: EXPERIMENTAL
Intervention: Gatifloxacin regimen (4 months with isoniazid, rifampicin, and pyrazinamide for first 2 months)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Moxifloxacin regimen (4 months with isoniazid, rifampicin, and pyrazinamide for first 2 months)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control regimen (6 months with isoniazid, rifampicin, ethambutol, and pyrazinamide for first 2 months)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Gatifloxacin regimen (for drug-resistant patients)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control regimen (for drug-resistant patients)
Number of subjects: 416
Study: 20934277

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (55 Gy in 20 fractions within 4 weeks)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Conventional radiotherapy (64 Gy in 32 fractions within 6.5 weeks)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 217

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 217
Study: 19346845

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (NTG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without NTG)
Number of subjects: 30
Study: 16720918

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, three times daily) and alpha-tocopherol (300 mg, twice daily) during radiotherapy, followed by 400 mg of PTX and 300 mg of alpha-tocopherol daily for 3 months after radiotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Radiotherapy only (control group)
Number of subjects: 66
Study: 15292629

Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (12 sessions, 90 minutes each)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 11743460

Group type: EXPERIMENTAL
Intervention: Sepragel sinus (hylan B gel)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 10